企业动态诺和诺德 (Novo Nordisk)首席执行官Lars Fruergaard Jorgensen于5月16日宣布辞职，该公司称此举归因于近期市场挑战。 这家丹麦制药巨头表示，Jorgensen将在岗位上留任 “一段时间，以支持向新领导层的平稳过渡”。公司补充称，目前正在寻找替代人选，并将在适当时候宣布结果。这一决定做出之际，诺和诺德的股价在过去一年中遭受重创，原因是迅速膨胀的肥胖症药物市 ...

Eli Lilly is turning up the volume on gene therapy with a $1.3 billion partnership with Rznomics to tackle sensorineural ...

2025年5月第三周，陆港两地创新药板块共计39个股上涨，67个股下跌。其中涨幅前三为德琪医药-B（18.34%）、思路迪（14.57%）、嘉和生物-B（14.48%）。跌幅前三为歌礼制药-B（-17.10%）、康宁杰瑞制药-B（-8.72%）、云顶新耀-B（-7.77%）。

Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA-based gene therapies for sensorineural ...

Rebrain SAS's Optimmri platform received European Medical Device Regulation CE mark certification to enable surgeons to ...

The deal gives Lilly access to the company’s RNA-editing platform to develop therapies for sensorineural hearing loss.

Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, has entered into a ...

Lilly will use Rznomics’ proprietary ribozyme technology to develop RNA editing therapies for congenital hearing loss.

Eli Lilly is further expanding its RNA medicine strategy by tapping South Korea’s Rznomics for a $1.3 billion biobucks deal ...

Eli Lilly is building out its gene therapy pipeline for hearing loss through a new deal with RNA-focused startup Rznomics.

Rznomics Inc. scored a potential ₩1.9 trillion (US$1.35 billion) global license option agreement with Eli Lilly and Co. to codevelop a novel RNA editing gene therapy to treat hereditary hearing loss.

Eli Lilly signs a global licensing deal with Rznomics to co-develop RNA-editing therapies for hearing loss, with potential ...